

Mayara Ivani de Paula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6081570/publications.pdf>

Version: 2024-02-01

10
papers

134
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

267
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti- θ thymocyte globulin without CMV prophylaxis – a cohort single-center study. <i>Transplant International</i> , 2021, 34, 339-352.	1.6	6
2	Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment. <i>Clinical Transplantation</i> , 2019, 33, e13689.	1.6	5
3	Prospective randomized study comparing everolimus and mycophenolate sodium in <i>de novo</i> kidney transplant recipients from expanded criteria deceased donor. <i>Transplant International</i> , 2019, 32, 1127-1143.	1.6	15
4	Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. <i>Transplant Infectious Disease</i> , 2019, 21, e13106.	1.7	10
5	Early hospital readmission after kidney transplantation under a public health care system. <i>Clinical Transplantation</i> , 2019, 33, e13467.	1.6	13
6	Randomized Trial of Machine Perfusion Versus Cold Storage in Recipients of Deceased Donor Kidney Transplants With High Incidence of Delayed Graft Function. <i>Transplantation Direct</i> , 2017, 3, e155.	1.6	41
7	Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). <i>Value in Health Regional Issues</i> , 2017, 14, 108-115.	1.2	6
8	mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 367-385.	3.3	9
9	The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2017, 39, 413-423.	0.9	12
10	Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 22-31.	2.0	17